# Adjunctive Lisdexamfetamine (LDX) in Bipolar Depression

> **NCT01131559** · PHASE3 · TERMINATED · sponsor: **Lindner Center of HOPE** · enrollment: 50 (estimated)

## Conditions studied

- Bipolar
- Depression

## Interventions

- **DRUG:** Lisdexamfetamine
- **DRUG:** Placebo control

## Key facts

- **NCT ID:** NCT01131559
- **Lead sponsor:** Lindner Center of HOPE
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2010-01
- **Primary completion:** 2014-02
- **Final completion:** 2014-02
- **Target enrollment:** 50 (ESTIMATED)
- **Why stopped:** Sponsor halted study.
- **Last updated:** 2014-03-05

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01131559

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01131559, "Adjunctive Lisdexamfetamine (LDX) in Bipolar Depression". Retrieved via AI Analytics 2026-07-16 from https://api.ai-analytics.org/clinical/NCT01131559. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*